Banner - NPPA Connect
Opinion|Videos|March 23, 2026

Key Takeaways on Psoriasis Treat-to-Target Goals

Explore innovative strategies for treating psoriasis, emphasizing patient communication and evolving treatment goals for better outcomes.

The panel concludes by emphasizing that treat-to-target strategies and achieving complete clearance are now realistic and essential goals in psoriasis care, thanks to scientific advances. Key final points stress there is no "standard" patient; care must be personalized as psoriatic disease evolves.

Effective care requires active listening, clear communication, and addressing patient-reported quality of life. Clinicians should feel empowered to make timely treatment changes (such as optimizing, switching, or combining therapies) without delay when goals aren't met. Lofty targets inspire better outcomes, and while not every patient achieves complete clearance, aiming high will benefit more patients. The future is optimistic, with evolving science making concepts like on-drug remission increasingly attainable, marking a significant advancement in psoriasis management.

Related to this article

Day 3 Recap: Fall Clinical 2026
Day 3 of Fall Clinical 2026 featured roflumilast data in genital psoriasis, long-term JAK inhibitor safety in atopic dermatitis, and expert insights on setting expectations in HS, treating advanced cSCC, and screening aesthetic patients.
Day 2 Recap: Fall Clinical 2026
The second day of Fall Clinical 2026 brought new psoriasis data on ixekizumab plus tirzepatide and 2-year icotrokinra results, along with 3-year nemolizumab findings, upadacitinib switch data, and expert guidance on choosing a biologic in atopic dermatitis.